TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of risks recalled
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Airways Resistance (IOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reactance Area (Ax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resonant Frequency (Fres)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve (AUC) to last time point (t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of drug (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DNA methylation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Dietary Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child PTSD Symptom Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survivorship: length of time implant remains without revision
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in Beck Anxiety Inventory (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical performance of the Meritas Troponin I test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Outcomes after shoulder surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fasting plasma FGF-23 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting serum osteocalcin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting serum insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Teacher Rating of Social Competence Scale (TRSCS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Academic Competence Evaluation Scale (ACES)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain immediately after insertion of first laminaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Direct Sunlight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pruritus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Metabolic control HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Weekly Mean 24-hour Average Pain Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of overall IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of abdominal bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stroke outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Timed 2 minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG (Time up and go) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM (Functional Independence Measure)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change from baseline pain to average 24-hour pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of left ventricular ejection fraction above 35% and NYHA class lower than II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Bowel Movement Within 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intrauterine bacteria count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mother-Infant Bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Spinal circuit excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Motor neuron excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in spinal reflex expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in descending drive mediated motor priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With a Treatment-related Immunologic Effect
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in A1C at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Down stage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing Treatment Due to Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Parasitological cure rate at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of sustained virological response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of risky drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of illicit alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of unprotected sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-disclosure of HIV status to sex partners
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in circulating insulin around an exercise bout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in circulating growth hormone around an exercise bout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Compositional Muscle Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of DW1029M in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of patients undergoing domino therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myofiber Helix Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IUD expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive affected domains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Thickness by caliper (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient satisfaction quartile scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infection within 30 days of injury
Endpoint domain: Adverse events/effects
Primary endpoint: child maltreatment reports
Endpoint domain: Adverse events/effects
Primary endpoint: injury to children
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Meningococcal C Serum Bactericidal Assay (SBA-MenC) Antibody Titers Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With SBA-MenA Antibody Titers Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Seroprotected (SPR) Subjects With Anti-Polyribosyl Ribitol Phosphate Anti-(PRP) Antibody Concentrations Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stress and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metastasis-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of BP estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting Inspiratory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory Capacity during Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ischaemic events via troponin Ic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cosmesis score at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cosmesis score at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Muscle protein synthesis (FSR in %/h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Progression
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of PF-05190457
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters (AUC, Cmax, Tmax, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in left ventricular mass by cine-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of tolterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of tolterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fermentation Profile- Short Chain Fatty Acid Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Microbial Population and Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant abnormalities requiring secondary intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Time to normalization of airway symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline the local kyphotic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to repeated hospitalizations for cardiovascular reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference in aPTT (activated partial prothrombin time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of life of the parents
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental health of the parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health-related quality of life of the chronically-ill children/adolescents
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma concentrations of Zol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentrations of Zol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jawbone tissue concentrations of Zol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian Reserve - AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovarian Reserve - FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovarian Reserve - Menstrual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal cognitive assessment test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: P300 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Testosterone Area Below Baseline Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: International Prostate Specific Symptom (IPSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS Global Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Who Achieved Clinical Response 50 (CR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of Ultrasound for VOD/SOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year Survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean Critical Flicker Fusion Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantification of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of catheter related blood infections
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical evolution of post-traumatic intracerebral hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scar Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sensory and motor deficits analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VTE/PE
Endpoint domain: Mortality/survival
Primary endpoint: incidence of ≥G2 xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength of the quadriceps femoris muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Successful Deployments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Helmet Deployment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Diary-based Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Viral Load-time Curve (VL-AUC) of RSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With RT-PCR Confirmed (Detected) Incidence of Symptomatic Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sum Total Symptoms Diary Card Score (TSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: VTI measurement concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Serious Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Major Hypoglycaemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score 28 Joint (DAS28) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Concentrations of Cerebral Energetic Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of the sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRCA1 or BRCA2 mutation positive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimal transplantation related mortality
Endpoint domain: Mortality/survival
Primary endpoint: High disease-free survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change in Ambulation Using the 6 Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of cases of NMO or NMOSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Overall Confirmed Response Rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Score Overall Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Score Overall Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change on the PDDBI Autism Composite Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change on the ABC-C Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change on the ATEC Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin microcirculation flow changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Use of additional uterotonics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of related Grade 3 and 4 adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of intraoperative and postoperative preretinal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reabsorption time of blood around the disc area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving Significant Improvement of Liver Cancer Pain/Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS Scale assessment
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Child's lean mass and fat mass (body composition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's length in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in salivary cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hemoglobin A1c change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of PHG and EVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Polysomnographic Total Sleep Time (TST)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: on-going pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Variation of mutational profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Objective Radiographic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance of posterior displacement of the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Defecation frequency per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal incontinence frequency per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall treatment success after 4 weeks of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ventriculoperitoneal shunt-dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: amount of exudate from post-op wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of seromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with Patient Benefit Index score (PBI-S) ≥1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance High Contrast logMAR Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing emergent or worsening of EPS
Endpoint domain: Adverse events/effects